1. Scrip
  2. >>Therapy Areas

Interview: Oryzon Chief Highlights CNS Opportunities

 
• By Kevin Grogan

After the setback of Roche pulling the plug on a potentially lucrative cancer partnership last year, the Spanish biotech tells Scrip it has bounced back with a compound that shows potential in Alzheimer's, multiple sclerosis and other neurodegenerative and psychiatric diseases.

Carlos Buesa
Carlos Buesa (left) speaking to Scrip at BioSpain • Source: Miguel Mendez

Oryzon Genomics SA, one of the leading lights in the Spanish biotech sector, hopes that with vafidemstat, it may have a molecule that can be a 'pipeline-in-a-product' to serve as a treatment for a wide range of central nervous system (CNS) diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.